secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0000950170-24-047941
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel to present CAN-3110 glioma data and CAN-2409 NSCLC topline OS at ASCO 2024
--------------------------------------------------------------------------------

- Two abstracts accepted for ASCO 2024: CAN-3110 phase 1 (recurrent high-grade glioma, cohort C) and CAN-2409 phase 2 (NSCLC with inadequate ICI response).
- CAN-3110 data: multiple injections (up to six) feasible and well tolerated in cohort C.
- CAN-2409 presentation will show topline overall survival data with valacyclovir + continued ICI.
- Presentations on June 1 (CAN-3110) and June 3 (CAN-2409) at ASCO in Chicago.
- Full abstracts released by ASCO on May 23, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/0000950170-24-047941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/cadl-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-047941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer